Stockreport

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026  Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key mile [Read more]